2007
DOI: 10.1001/jama.298.2.187
|View full text |Cite
|
Sign up to set email alerts
|

Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

8
162
3
10

Year Published

2007
2007
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 257 publications
(183 citation statements)
references
References 28 publications
8
162
3
10
Order By: Relevance
“…On the other hand, several clinical trials suggest beneficial metabolic effects for anti-malaria agents that prevent acidification of lysosome-related compartments [100]. This would suggest that inhibition of autophagy or other lysosomal functions may turn out to be beneficial, probably due to inhibition of hepatic insulin degradation [101] or, as more recently proposed, by inhibiting lysosome-dependent lipolysis in adipose tissue macrophages [11].…”
Section: Autophagy In Beta Cell Physiology and Diabetesmentioning
confidence: 99%
“…On the other hand, several clinical trials suggest beneficial metabolic effects for anti-malaria agents that prevent acidification of lysosome-related compartments [100]. This would suggest that inhibition of autophagy or other lysosomal functions may turn out to be beneficial, probably due to inhibition of hepatic insulin degradation [101] or, as more recently proposed, by inhibiting lysosome-dependent lipolysis in adipose tissue macrophages [11].…”
Section: Autophagy In Beta Cell Physiology and Diabetesmentioning
confidence: 99%
“…Also, such tests showed a tendency towards an improved lipid profile in the chloroquine group at six months follow up and, although time of follow up was short, there are reports about the favorable features of antimalarials towards dyslipidemia and diabetes development. We believe a research about this should be considered in patients with dyslipidemia or glycemic dysregulation associated with antiretrovirals [18,19]. The T CD4+ cells count was below than 100/mcL at baseline in both groups, which added to the opportunistic diseases, and confirmed a C3 CDC stage at the beginning of therapy.…”
Section: Discussionmentioning
confidence: 73%
“…So, our study aimed to investigate the association between HCQ treatment use and diabetes mellitus risk in SLE patients. The mechanism of action of HCQ as a hypoglycemic drug appears in those patients through the better control of glucose levels , improve insulin secretion, decreased insulin resistance, and lower levels of hemoglobin A1c [10,32].…”
Section: Discussionmentioning
confidence: 99%
“…HCQ had a hypoglycaemic effect in patient with SLE due to different reasons as the inhibition of intracellular degradation of insulin [9,10]. The risk of incident diabetes was found to be reduced with increased duration of therapy [11][12][13].…”
Section: Introductionmentioning
confidence: 99%